# Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

> **NCT02076100** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Hepatitis C Infection

## Interventions

- **DRUG:** Ruzasvir

## Key facts

- **NCT ID:** NCT02076100
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2015-11-15
- **Final completion:** 2015-11-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076100, "Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02076100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*